로딩 중…
StockDiggingStockDigging

Celltrion Pharm, Inc.

068760· KOSDAQ
₩41,900-3.23%
2026-06-19

Price Chart

Celltrion Pharm, Inc.-13.85%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap1.86T KRW
Revenue556.00B KRW
Net Income40.25B KRW
Total Assets768.81B KRW
Net Assets434.82B KRW
Employees920
Value
P/E46.22x
P/B4.28x
PEG2.26x
P/S3.35x
EV/EBITDA122.45x
FCF Yield3.78%
Profitability
ROE9.26%
ROA5.24%
Op. Margin10.48%
Revenue Growth17.42%
Earnings Growth20.44%
Financial Health
Debt Ratio176.81%
Total Debt142.00B KRW
FCF70.27B KRW
Cash56.79B KRW
Current Ratio1.65x
Net Debt/EBITDA5.36x
Dividend
Div. Yield0.45%
Performance
1Y Return-13.85%
1M Return-10.85%
From 52W High-46.49%
1Y MDD-46.50%
Trading
Volume129,958 shares
Foreign Own.5.27%
Per Share
EPS903 KRW
BPS9,849 KRW

Company Info

CEO 유영호
Employees 920
Founded 2000
HQ 충청북도 청주시, KR

This specialized pharmaceutical manufacturing and sales company was established in 2000 and listed on KOSDAQ in 2006. It operates KGMP, US cGMP, and EU-GMP certified facilities in Ochang and Jincheon, Chungcheongbuk-do, producing specialized pharmaceuticals and biopharmaceuticals via PFS production lines. The company holds domestic exclusive sales rights for chemical pharmaceuticals like the liver disease treatment Godex, and 12 biopharmaceuticals, including autoimmune disease treatments and anti-cancer drugs developed by its parent company, Celltrion, while actively pursuing pipeline expansion and technological platform innovation.